Literature DB >> 2867880

Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man.

A Tsuji, K Nishide, H Minami, E Nakashima, T Terasaki, T Yamana.   

Abstract

In the present study, the physiologically based pharmacokinetic model, which succeeded previously in predicting the pharmacokinetics of beta-lactam antibiotics in rats [A. Tsuji, T. Yoshikawa, K. Nishide, H. Minami, M. Kimura, E. Nakashima, T. Terasaki, E. Miyamoto, C.H. Nightingale, and T. Yamana: Physiologically based pharmacokinetic model for beta-lactam antibiotics. I: tissue distribution and elimination in rats. J. Pharm. Sci. 72, 1239-1252 (1983)], was applied to cefazolin pharmacokinetics in rabbits and man. After iv bolus dosing in normal rabbits, the time courses of cefazolin concentration in plasma and various tissues (lung, heart, muscle, skin, bone, gut, liver, and kidney) were found to be very similar to those in rats. The values of physiological parameters (tissue plasma flows, tissue volumes, tissue/plasma albumin ratio) and biochemical parameters determined in this study (for nonlinear plasma protein binding, intrinsic renal clearance of active secretion and reabsorption) were incorporated into mass balance equations derived from the model. There was reasonable agreement between the model predictions and the observed data for cefazolin and inulin in rabbits. The model was also successful in the prediction of cefazolin disposition in rabbits with renal failure. Using available information reported for cefazolin in man, a preliminary extrapolation from the present model was attempted, and the overall predicted results after iv administration of 1 g cefazolin in man were compared with the serum and bone tissue data. The length of the effective antibacterial period for the drug is also discussed in terms of its predicted concentration unbound with proteins in various tissue interstitial fluids in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867880

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Dynamics of drug distribution. I. Role of the second and third curve moments.

Authors:  M Weiss; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

Review 3.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

4.  Lumping of whole-body physiologically based pharmacokinetic models.

Authors:  I A Nestorov; L J Aarons; P A Arundel; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

5.  Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

Authors:  Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 6.  The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.

Authors:  Qingyu Zhou; James M Gallo
Journal:  AAPS J       Date:  2011-01-19       Impact factor: 4.009

7.  Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

8.  Alterations in pharmacokinetics and protein binding behavior of cefazolin in endotoxemic rats.

Authors:  M Nadai; T Hasegawa; K Kato; L Wang; T Nabeshima; N Kato
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

9.  Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts.

Authors:  R Koshida; E Nakashima; N Taniguchi; A Tsuji; L Z Benet; F Ichimura
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

10.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.

Authors:  R Kawai; M Lemaire; J L Steimer; A Bruelisauer; W Niederberger; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1994-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.